Study: Most consumers now opt for private labels
The Consumer Products Engagement report highlights brands' growing challenge in retaining customer loyalty.
Research
Deloitte: GLP-1s drive surge in pharmaceutical R&D returns
GLP-1 therapies emerge as a key driver of industry return on investment.
Olio Labs study shows why women experience more GLP-1 side effects
With the obesity treatment market expected to reach $200 billion by 2031, this study could greatly influence future therapeutic approaches.
NielsenIQ study: Discount retailers and private labels gain ground
Private-label brands are now a primary growth driver for 53% of retailers. Once seen as budget alternatives, they are evolving into premium and innovative choices.
Evaluate releases 2025 Orphan Drug Report
Report reveals orphans’ growth advantage over non-orphans is narrowing, begging the question - are these drugs still a class apart?
New study: Pharmacies can help combat substance abuse
“These findings reinforce the impact of innovative partnerships in improving health outcomes,” says the NACDS Foundation president.
Americans over 55 report optimism for their health and the future
However, an undercurrent of mental health threats loom.
FMI: Produce shoppers prioritize convenience and are influenced by social media
“Younger shoppers, particularly Millennials and Gen Z, are driving significant shifts in the produce industry.”
Social media flooded with misleading medical test promotions, study warns
The study's authors stress that misleading promotion of medical tests can lead to overdiagnosis.
NielsenIQ on the role of technology in wellness for 2025
NielsenIQ reports that consumers are embracing digital-first wellness solutions at an unprecedented rate.
Report from CoverMyMeds looks at actionable strategies to bridge gaps for patients
CoverMyMeds' 2025 Medication Access Report: From Barriers to Bridges calls for increased collaboration and interoperability across the healthcare industry to improve patient outcomes.
New report from GoodRx tracks changes in GLP-1 insurance coverage
In 2025, the number of people without commercial insurance coverage for these medications surged significantly. Zepbound saw a 14% increase since 2024, leaving 4.9 million people without coverage, and Ozempic saw a 22% increase, affecting another 1.1 million people.
Study reveals the protein snack phenomenon is racing through the $126B snacking market
Protein snacks reached $24B in sales and are growing at three times the rate of the overall snacking category.
Circana global research showcases the power of private label transformation
Elevated prices and pressured consumers set the stage for increasing retailer investment and consumer adoption, leading to private label share growth in CPG globally.
New research from Zebra reveals growth in warehouse modernization
According to the study, 63% of warehouse leaders plan to implement artificial intelligence software and augmented reality within five years.
Acosta study reveals rising demand for natural and organic products
Younger generations are leading the demand, with 89% of Gen Z and 85% of Millennials purchasing natural and organic items.
